Board of Directors

Nationality: British

Committee memberships:  Environmental, Social and Governance Committee (Chair), Investment Committee, Nomination Committee (Chair), Remuneration Committee 

Appointed: Chair Designate March 2020, Chair July 2020 

Contribution to the Company 

Dame Inga has close to 40 years of business management and leadership experience in global financial services, insurance and risk management in particular, and contributes a wealth of other skills and experience to the Board. As CEO of Lloyd’s of London, the insurance and reinsurance market, she initiated large-scale digital and cultural transformation programmes and led the business’s expansion into Dubai, China and India. She also played a critical role in advancing diversity and inclusion initiatives across Lloyd’s and the international insurance sector. Her background provides a valuable balance to the Board and brings a different perspective to the Board’s debates.

Career experience

From 2014 to 2018 she served as the first female CEO of Lloyd’s of London. Previously she held various senior leadership positions across the insurance sector, both in Switzerland and internationally, including at Converium, Zurich Insurance Group, Canopius and GE Insurance Solutions.

Key external appointments

Independent non-executive director of Crawford & Company and London First. She serves on the London Mayor’s Business Advisory Board and is Patron of Insuring Women’s Futures. She has recently been appointed to the supervisory board of NN Group N.V.

Qualifications

Associate of the Chartered Insurance Institute since 1987, appointed Dame Commander of the Order of the British Empire in 2017 for services to the UK economy.

Nationality: South African

Committee membership: Clinical Performance Committee, Environmental, Social and Governance Committee, Investment Committee

Appointed: June 2018

Contribution to the Company 

Dr Van der Merwe has a strong track record of leadership and management within a large private sector healthcare organisation, including strategy, organisational development, clinical performance, adoption of technology and managing quality. He also has extensive knowledge of Mediclinic’s operations. As a qualified anaesthesiologist in private practice, Dr Van der Merwe gained extensive experience in trauma and elective anaesthesia, intensive care management, and the management of acute and chronic pain. During his involvement in the medical insurance industry, he gained expertise in healthcare data management, analytics, managed healthcare principles and reimbursement models. He established the Clinical Services, Clinical Information, Advanced Analytics, Health Information  Management and central Procurement functions at Mediclinic, contributing to the growth and strategic positioning of the Group.

Career experience

He joined the Company in 1999 and as Chief Clinical Officer took responsibility for various aspects of the business prior to his appointment as executive director and Group CEO of Mediclinic. He was an executive director of Mediclinic International Ltd from 2010, up to the reverse takeover of Al Noor Hospitals Group plc. He was appointed as an executive director and Group CEO of Mediclinic, with effect from 1 June 2018, and also serves as a non-executive director of Spire since 24 May 2018 under the terms of the shareholder agreement between Spire and Mediclinic.

Key external appointments

Non-executive director of Spire.

Qualifications

MBChB (Stellenbosch University), DA (SA) (College of Anaesthetists of South Africa), FCA (SA) (Fellowship of the College of Anaesthetists of South Africa), Advanced Management Program (Harvard Business School).

Nationality: South African

Committee membership: Investment Committee    

Appointed: August 2016

Contribution to the Company 

Mr Myburgh is a qualified chartered accountant with broad financial and accounting experience obtained during his career of over 20 years. Since joining the Group, he has emphasised the importance of capital management and allocation informed by cost of capital across the Group and driven a structured approach to growth.

Career experience

After qualifying as a chartered accountant with KPMG in 2000, he joined The Standard Bank of South Africa Ltd in 2001 and was appointed as Head of Mergers and Acquisitions in 2009. Subsequently, he served as CFO at Datatec Ltd, an international ICT Group, before joining Mediclinic as Group CFO in August 2016.

Key external appointments

None.

Qualifications

BComm Hons in Accounting (University of Johannesburg), registered with the South African Institute of Chartered Accountants.

Nationality: British

Committee memberships: Clinical Performance Committee (Chair), Environmental, Social and Governance Committee, Nomination Committee    

Appointed: Independent non-executive director October 2017, Senior Independent Director September 2021

Contribution to the Company 

Dr Harvey’s clinical and public health background provides valuable balance to the Board and brings an important perspective to the Board’s discussions and to the Clinical Performance and Sustainability Committee, particularly as developments in technology continue to accelerate. She also plays a crucial role in supporting management in the development and implementation of the Company’s sustainability strategy.

Career experience

Throughout her career, Dr Harvey has gained an indepth knowledge of the health sector, mainly through her work in the medical field. She is a clinician by background and was previously Director General for Public and International Health at the UK Department of Health; Director of the UK Prime Minister’s Delivery Unit; Head of the Medicines, Pharmacy and Industry Group at the Department of Health; Director of Prison Health at Her Majesty’s Prison Service; Head of Quality Management at NHS Executive; and Private Secretary to the Chief Medical Officer.

Key external appointments

Non-executive director of Guy’s and St Thomas’ NHS Foundation Trust, London; non-executive director of Halcyon TopCo Ltd; visiting professor at the Institute of Global Health Innovation, Imperial College London; Chair of the World Health Organization Independent Oversight and Advisory Committee for Health Emergencies.

Qualifications

MBBS (St Bartholomew’s Medical College, University of London), PgDip in Clinical Microbiology (The Royal London Hospital College, University of London), MBA (Henley Management College). She was appointed Commander of the Order of the British Empire in 2008, and is an Honorary Fellow of the Royal College of Physicians and a Fellow of the Faculty of Public Health, as well as a member of Chapter Zero, the UK Chapter of the World Economic Forum’s Climate Governance Initiative.

Nationality: Emirati

Committee membership: Clinical Performance Committee, Remuneration Committee

Appointed: November 2017

Contribution to the Company 

Dr Al Hashimi has extensive knowledge and experience of the healthcare sector and provides substantial strategic and tactical expertise in operations, fiscal management and negotiating strategic transactions. She contributes valuable insights, especially into the Middle East operations of the Company, and has an excellent understanding of the broader geopolitical landscape.

Career experience

Dr Al Hashimi has over 20 years’ experience in the healthcare and higher education industry in the UAE. She is currently the Chair of the Sharjah Private Education Authority. Previous roles include serving as CEO of Dubai Healthcare City; CEO of the Mohammed Bin Rashid Al Maktoum Academic Medical Center; Deputy CEO of Tatweer; Member of Dubai Holdings; Executive Dean of the Faculty of Health Sciences, Higher Colleges of Technology (‘HCT’); Acting Deputy Vice Chancellor of Academic Affairs at HCT; and a Director of Education of the Harvard Medical School Dubai Center.

Key external appointments

Member of the University of Sharjah board of trustees, member of the Audit and Compliance Committee and the Academic Committee of the University of Sharjah, and a trustee of the UAE Nursing and Midwifery Council and the UAE Genetic Diseases Association.

Qualifications

BS in Medical Technology (University of Minnesota), MSc in Clinical Laboratory Services (University of Minnesota), Doctor of Public Health (University of Texas).

Nationality: French, Russian

Committee membership: Audit and Risk Committee, Environmental, Social and Governance Committee

Appointed: August 2021

Contribution to the Company 

Natalia Barsegiyan is a former Chief Commercial Officer of Yum! Brands, Inc. (owner of a portfolio of many well-known brands such as KFC, Pizza Hut and Taco Bell) and former Chief Financial Officer of Taco Bell. A certified professional accountant (RF CPA) and certified management accountant (USA CMA), she brings a strong finance background with a commercial and strategic focus, an in-depth understanding of the use of data analytics to support transformation, and broad international experience having lived and worked across the US, Europe, Russia and the UK.

Career experience

Prior to moving on to advisory and non-executive roles, the majority of Ms Barsegiyan's career was with the US group Yum! Brands, Inc., where she worked in substantial financial leadership roles, across different geographies and structures.

Key external appointments

Non-executive director of Domino's Pizza Group plc and a member of their Audit, Remuneration and Nomination Committees. Ms Barsegiyan also acts as an adviser to Kharis Capital, a private equity firm based in Belgium.

Qualifications

MEng in Electrical Engineering (State University of Transportation, Russia), MBA (Academy of National Economy of Russia) and executive education programmes on: Valuation, Mergers and Acquisitions (Harvard); Financial Management (Stanford Graduate School of Business); and Organisational Design for Digital Transformation (MIT Sloan School of Management).

Nationality: South African

Committee memberships: Investment Committee (Chair), Nomination Committee

Appointed: February 2016*

Contribution to the Company 

Mr Durand has extensive knowledge and over 20 years’ experience in the investment industry bringing substantial strategic and tactical expertise. He contributes valuable insights to the Board’s discussions by drawing on his skills and experience of the investment and capital markets, finance andaccounting, risk management, development and implementation of strategy, as well as investor relations.

Career experience

He served as non-executive director of Mediclinic International Ltd from 2012 up until the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016. He joined the Rembrandt Group in 1996 and in 2012 was appointed as the CEO of Remgro, which holds a 44.56% interest in the Company, serving as its representative on the Board.

Key external appointments

Non-executive chair for the following listed companies within the Remgro group: Distell Group Holdings Ltd, RCL Foods Ltd and Rand Merchant Investment Holdings Ltd.

Qualifications

BAcc Hons in Accountancy (Stellenbosch University), MPhil in Management Studies (Oxford University), registered with the South African Institute of Chartered Accountants.

* Mr Uys, the Head of Strategic Investment at Remgro, was appointed as the alternate director to Mr Durand in April 2016. Prior to joining Remgro, he was a founding member and ultimately became the CEO of the Vodacom Group. He holds an MEng in Electronic Engineering (Stellenbosch University) and an Executive MBA (Stellenbosch University).

Nationality: British and Swiss

Appointed: February 2016

Contribution to the Company 

Working as an executive and non-executive director across a wide range of business areas, Mr Grieve has gained comprehensive experience in finance, accounting and risk management; he also has extensive knowledge of the healthcare sector. This equips him with a strong basis for assessing and, where appropriate, challenging the financial and risk management framework.

Career experience

He began his career in accountancy at the respective auditing firms now known as PwC and EY. He worked for Richemont, the Swiss luxury goods group, as Company Secretary from 1998 to 2004 and as Director of Corporate Affairs from 2004 to 2014. He served as an independent non-executive director of Mediclinic International Ltd from 2012 and as a director of Mediclinic Switzerland AG (now Hirslanden AG) between 2008 and 2012. He served as CFO of Reinet Investments Manager SA and Reinet Fund Manager SA from 2008 to 2011 and was the CEO from 2012 until he retired in 2014.

Key external appointments

Non-executive director Reinet Investments Manager SA and Reinet Fund Manager SA.

Qualifications

BA Hons Business Administration (Heriot-Watt University), member of the Institute of Chartered Accountants of Scotland.

Nationality: South African

Committee membership: Environmental, Social and Governance Committee, Investment Committee

Appointed: Non-executive director August 2018, designated non-executive director for workforce engagement April 2019

Contribution to the Company 

As the former Group CEO and prior to that, as divisional Human Resources Executive, Mr Meintjes led Mediclinic’s efforts to engage with, and invest in, the Company’s workforce. With his career background and in-depth knowledge of the Company, he is uniquely positioned to effectively oversee the Company’s employee engagement processes and evaluate the effectiveness and progress in this regard. He brings significant operational, strategic and risk management experience to the Board as well as extensive knowledge of the healthcare sector.

Career experience

He served as CEO of Mediclinic from 2010 up to his retirement on 1 June 2018. He was appointed as an executive director and Group CEO of the Company on 15 February 2016. Mr Meintjes served in various management positions in the Remgro group before joining Mediclinic in 1985 as the Hospital Manager of Mediclinic Sandton. He became a member of Mediclinic’s Executive Committee in 1995 and a director in 1996. In 2006 he was seconded to serve as a senior executive of the Group’s operations in Dubai and appointed as the CEO of Mediclinic Middle East in 2007. He served as a non-executive director of Spire from 2015, a position from which he retired on 24 May 2018.

Key external appointments

Non-executive director of Capitec Bank Holdings Ltd and Capitec Bank Ltd.

Qualifications

BPL Hons in Industrial Psychology (University of the Free State), Advanced Management Program (Harvard Business School).

Nationality: Swiss

Committee memberships: Clinical Performance Committee, Nomination Committee 

Appointed: July 2018

Contribution to the Company

Dr Oswald supports the Board with her knowledge and experience in digital transformation and digital ecosystems as well as with her tremendous network in different fields. In addition, with her unique insights into day-to-day operations in the broader political and regulatory context of private healthcare in Switzerland and her experience as a medical specialist, general manager and board member of various companies and start-up companies, she brings a wealth of knowledge and practical experience.

Career experience

She was previously Deputy Medical Officer in the Department of Health, Head of Medical and Pharmaceutical Services, as well as a member of various cantonal, regional and national committees in Swiss health administration authorities and worked closely with political opinion leaders. She was also CEO of a healthcare start-up company and worked for several years as a medical specialist in various hospitals.

Key external appointments

CEO of Klinik Sonnenhalde AG, member of the boards of Integrierte Psychiatrie Winterthur, Zippsafe AG, a spin-off of ETH in the industry field that produces smart locker solutions, and Past-President of the Association of Private Hospitals in Basel.

Qualifications

MD-PhD (University of Basel), specialising in Orthopaedic Surgery and Traumatology, as well as in Sports Medicine, Executive MBA (University of Rochester-Bern). She holds a certificate in General Management (University of Bern) as well as a certificate of the Swiss Board School (International Center for Corporate Governance of the University of St. Gallen).

Nationality: South African

Appointed: February 2016

Contribution to the Company

Mr Petersen brings significant experience, in-depth knowledge and corporate history of Mediclinic and the healthcare sector, having served as a director from 2012 and through the successful merger of Mediclinic International and Al Noor Hospitals Group plc in February 2016. Through his career in accountancy and audit, Mr Petersen has valuable experience, which informs his role on the Mediclinic Board and its committees.

Career experience

Previously a lecturer at the University of Cape Town, he took up a partnership in the merged firm of PricewaterhouseCoopers Inc in 1996. He served as a partner of the national firm from 1997 to 2009 and as the partner-in-charge of Cape Town and Chair of the Western Cape region. He has served professional membership associations such as the South African Institute of Chartered Accountants and was elected the Chair of its national body in 2006 and 2007.

Key external appointments

Lead independent non-executive director of Media24 (Pty) Ltd.

Qualifications

BComm Hons in Financial Management (University of Cape Town), registered with the South African Institute of Chartered Accountants.

Nationality: British 

Committee memberships: Audit and Risk Committee (Chair), Investment Committee, Remuneration Committee

Appointed: July 2019

Contribution to the Company

Mr Singer’s skills and experience, gained through his long and successful career in finance across a broad range of UK and international branded consumer businesses, including in the healthcare sector, provide important input. He also brings a thorough understanding of the UK-listed company environment. His career and background make him ideally suited to succeed Mr Grieve as chair of the Audit and Risk Committee.

Career experience

Previously served as CFO of InterContinental Hotels Group PLC, a leading international hotel group, and British United Provident Association (‘BUPA’), a provider of health insurance, care homes for the elderly and other health-related services including private hospitals. Earlier in his career, Mr Singer was CFO and Chief Operating Officer of William Hill PLC and Finance Director of Moss Bros PLC, having started his career in professional services and spending a total of 12 years at Price Waterhouse and McKinsey.

Key external appointments

Non-executive director of Halfords Group plc and DP Eurasia NV, an operator of pizza restaurants in Turkey and Russia.

Qualifications

BSc Hons Finance and Accounting (University of Bristol), qualified chartered accountant, Advanced Management Programme (INSEAD).

Nationality: American

Committee memberships: Audit and Risk Committee, Clinical Performance Committee, Remuneration Committee (Chair)

Appointed: July 2020

Contribution to the Company

Mr Weiner brings significant healthcare and international consumer goods experience in executive and non-executive finance and business transformation leadership roles in large, complex organisations in developed and developing markets.

Career experience

He spent most of his career in finance with the international consumer goods group Unilever, most recently as Group Controller responsible for performance management, accounting, reporting and control. He was a member of Unilever’s Global Finance Leadership Team, working closely with the group’s board and Audit Committee. As non-executive director of Guy’s and St Thomas’ NHS Foundation Trust, one of the largest NHS Foundation Trusts in the UK, he chaired the Audit Committee from 2014 to 2018.

Key external appointments

Non-executive director of Guy’s and St Thomas’ NHS Foundation Trust and of King’s College Hospital NHS Foundation Trust.

Qualifications

Masters in Finance (Columbia University), BSc in Management (Rutgers University).